Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
25 February 2004Website:
http://www.oragenics.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:45:21 GMTDividend
Analysts recommendations
Institutional Ownership
OGEN Latest News
SARASOTA, Fla., June 27, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has completed a prototype of its automated intranasal device for use in concussed patients who are initially confused, dazed or unconscious in the acute phase of injury.
SARASOTA, Fla., June 26, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced the closing of its public offering of 1,100,000 shares of its common stock at an offering price of $1.00 per share.
Dr. Peacock to Oversee Upcoming Phase II Clinical Trial for Treating Concussion in the Emergency Department Dr. Peacock to Oversee Upcoming Phase II Clinical Trial for Treating Concussion in the Emergency Department
Oragenics, Inc., a pharmaceutical company known for its intranasal treatments for neurological disorders, will be hosting a webinar panel on Neurotrauma Medicine on May 20, 2024, at 12:00 PM ET.
Oragenics (NYSEMKT: OGEN ) stock is falling on Wednesday after the antibiotics development company announced details of a public offering for its shares. Oragenics is selling 1.4 million shares of OGEN stock for $1.50 each.
What type of business is Oragenics?
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
What sector is Oragenics in?
Oragenics is in the Healthcare sector
What industry is Oragenics in?
Oragenics is in the Biotechnology industry
What country is Oragenics from?
Oragenics is headquartered in United States
When did Oragenics go public?
Oragenics initial public offering (IPO) was on 25 February 2004
What is Oragenics website?
https://www.oragenics.com
Is Oragenics in the S&P 500?
No, Oragenics is not included in the S&P 500 index
Is Oragenics in the NASDAQ 100?
No, Oragenics is not included in the NASDAQ 100 index
Is Oragenics in the Dow Jones?
No, Oragenics is not included in the Dow Jones index
When does Oragenics report earnings?
The next expected earnings date for Oragenics is 09 August 2024